FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Trinity Capital Provides $40MM Term Loan to Taysha Gene Therapies

December 19, 2023, 07:55 AM
Filed Under: Medical
Related: Trinity Capital

Trinity Capital announced the commitment of $40 million in term loans to Taysha Gene Therapies, a clinical-stage gene therapy company, pursuant to a Loan and Security Agreement dated November 13, 2023, by and among Taysha, the lenders party thereto from time to time, and Trinity, as administrative agent and collateral agent for the Lenders.

Taysha is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system ("CNS"). Its lead clinical program TSHA-102 is in evaluation for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that treat the root cause of the disease. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and its intrathecal delivery in combination with a clinically and commercially proven AAV9 capsid, in an effort to translate treatments from bench to bedside.

"We are excited to partner with Taysha as it advances its lead gene therapy program in clinical evaluation for Rett syndrome, and believe Taysha has the potential to achieve significant advancements in the gene therapy field," said Igor DaCruz, Managing Director, Life Sciences at Trinity. "We look forward to working together with their management team as Taysha focuses on bringing novel treatments with disease-modifying potential for diseases, like Rett syndrome, with high unmet need."

With the term loan, Taysha believes it will be able to fund its operating expenses and capital requirements into 2026 to support the clinical development of its TSHA-102 program in Rett syndrome.

"We are highly encouraged by the support from Trinity, which we believe further reinforces Taysha's vision to transform the lives of patients suffering from devastating diseases through the development of AAV-based gene therapies," said Kamran Alam, Chief Financial Officer of Taysha. "With Trinity's support, we believe we are well-positioned to continue to execute across our near-term milestones for our TSHA-102 program in Rett syndrome."

Week's News

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.